Skip to main content
    G

    Gilead Sciences Inc (GILD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $157.37
    +3.83 (+2.49%)

    Market Cap: $190.38B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    74%(29/39)
    Avg Surprise
    +5.12%
    Streak
    10 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.16
    Range$1.90 - $2.68
    22 analysts
    EPS RevisionsNo revisions (7d)
    6
    14
    30d
    EPS Estimate DriftChange to current
    90d ago$2.08+4.0%
    60d ago$2.16+0.3%
    30d ago$2.14+0.9%
    7d ago$2.15+0.7%
    Current$2.16
    Revenue Consensus
    $7.8B
    Range$7.5B - $8.0B
    20 analysts
    Period ending Dec 31, 2026
    EPS Consensus$2.76
    Range$2.56 - $3.15
    27 analysts
    Revenue Consensus
    $8.6B
    Range$8.2B - $9.1B
    25 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.76---
    Sep 26EST
    		-$2.16---
    Jun 26
    Reported Aug 3
    		$-6.75$-7.07+4.53%Beat-435.8%
    Mar 26
    Reported May 7
    		$2.03$1.91+6.28%Beat+12.2%
    Dec 25
    Reported Feb 10
    		$1.86$1.81+2.76%Beat-2.1%
    Sep 25
    Reported Oct 30
    		$2.47$2.14+15.42%Beat+22.3%
    Jun 25
    Reported Aug 7
    		$2.01$1.95+3.08%Beat+0.0%
    Mar 25
    Reported Apr 24
    		$1.81$1.78+1.69%Beat+237.1%
    Dec 24
    Reported Feb 11
    		$1.90$1.70+11.73%Beat+10.5%
    Sep 24
    Reported Nov 6
    		$2.02$1.55+30.32%Beat-11.8%
    Jun 24
    Reported Aug 8
    		$2.01$1.60+25.63%Beat+50.0%
    Mar 24
    Reported Apr 25
    		$-1.32$-1.52+13.16%Beat-196.4%
    Dec 23
    Reported Feb 6
    		$1.72$1.76-2.27%Miss+3.0%
    Sep 23
    Reported Nov 7
    		$2.29$1.92+19.27%Beat+20.5%
    Jun 23
    Reported Aug 3
    		$1.34$1.64-18.29%Miss-15.2%
    Mar 23
    Reported Apr 27
    		$1.37$1.54-11.04%Miss-35.4%
    Dec 22
    Reported Feb 2
    		$1.67$1.51+10.60%Beat+142.0%
    Sep 22
    Reported Oct 27
    		$1.90$1.43+32.87%Beat-28.3%
    Jun 22
    Reported Aug 2
    		$1.58$1.52+3.95%Beat-15.5%
    Mar 22
    Reported Apr 28
    		$2.12$1.81+17.13%Beat+1.9%
    Dec 21
    Reported Feb 1
    		$0.69N/A-56.60%Miss-68.5%
    Sep 21
    Reported Oct 28
    		$2.65$1.78+48.88%Beat+25.6%
    Jun 21
    Reported Jul 29
    		$1.87$1.75+6.86%Beat+68.5%
    Mar 21
    Reported Apr 29
    		$2.08$2.11-1.42%Miss+23.8%
    Dec 20
    Reported Feb 4
    		$2.19$2.15+1.86%Beat+68.5%
    Sep 20
    Reported Oct 28
    		$2.11$1.89+11.64%Beat+20.6%
    Jun 20
    Reported Jul 30
    		$1.11$1.45-23.45%Miss-39.0%
    Mar 20
    Reported Apr 30
    		$1.68$1.56+7.69%Beat-4.5%
    Dec 19
    Reported Feb 4
    		$1.30$1.67-22.16%Miss-9.7%
    Sep 19
    Reported Oct 24
    		$1.75$1.73+1.16%Beat-4.9%
    Jun 19
    Reported Jul 30
    		$1.82$1.71+6.43%Beat-4.7%
    Mar 19
    Reported May 2
    		$1.76$1.60+10.00%Beat+18.9%
    Dec 18
    Reported Feb 4
    		$1.44$1.69-14.79%Miss-19.1%
    Sep 18
    Reported Oct 25
    		$1.84$1.63+12.88%Beat-18.9%
    Jun 18
    Reported Jul 25
    		$1.91$1.56+22.44%Beat-25.4%
    Mar 18
    Reported May 1
    		$1.48$1.67-11.38%Miss-33.6%
    Dec 17
    Reported Feb 6
    		$1.78$1.67+6.59%Beat-34.1%
    Sep 17
    Reported Oct 26
    		$2.27$2.13+6.57%Beat-
    Jun 17
    Reported Jul 26
    		$2.56$2.17+17.97%Beat-
    Mar 17
    Reported May 2
    		$2.23$2.28-2.19%Miss-
    Dec 16
    Reported Feb 7
    		$2.70$2.60+3.85%Beat-

    Dividends

    Dividend Metrics

    Forward Yield2.08%
    Forward Annual Dividend$3.28
    Payout Ratio29.81%
    FrequencyQuarterly
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+2.67%
    5Y CAGR+3.04%
    GILD dividend history and ex-dividend datesRun GILD in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio-403.51EV/EBITDA121.29x
    Price/FCF15.11xFCF Yield6.62%
    Profitability
    Profit Margin-10.60%Operating Margin33.70%
    ROE-20.70%ROIC-2.51%
    Financial Health
    Debt/Equity2.22xInterest Coverage10.57x
    Current Ratio1.27xQuick Ratio1.09x
    Trading Statistics
    Beta0.33Avg Volume6.02M
    52-Week High$154.5152-Week Low$111.27

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$148.80
    SMA 20$149.67
    SMA 50$145.90
    SMA 200$136.85
    EMA 10$150.73
    EMA 20$149.36
    EMA 50$145.54
    EMA 200$135.54

    MACD

    Line: 1.72Signal: 1.21Hist: 0.51

    ADX

    ADX: 22.3+DI: 35.6-DI: 15.3

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down72.0
    PSAR$144.13

    Bollinger Bands

    Upper Band$156.20
    Lower Band$143.14
    %B Position873%(Upper)
    Band Width1.09

    RSI (14-Day)

    Neutral
    66.4

    Momentum Oscillators

    Stoch %K77.3
    Stoch %D71.3
    Williams %R-17.5
    ROC (10d)6.7%
    Momentum9.87
    CCI (20d)243.8
    MFI (14d)52.7

    Volatility Measures

    ATR (14d)$3.96(2.5%)
    StdDev (20d)3.27
    Hist Vol24.9%(Moderate)

    Volume Flow

    VWAP$157.97
    OBV94.7M
    AD Line-2.0B
    CMF (20d)-0.066

    Volume Metrics

    Avg Vol (20d)6.0M
    Vol Ratio1.4x
    VWMA (20d)$150.01

    Pivot Points

    R3$161.99
    R2$157.87
    R1$155.71
    Pivot Point$151.59
    S1$149.43
    S2$145.31
    S3$143.15

    Advanced Oscillators

    TSI14.03
    Ultimate Osc61.8
    KST16.39

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.80B$6.96B$7.92B$7.77B$7.08B$6.67B$7.57B$7.54B$6.95B$6.69B$7.11B$7.05B
    Cost of Revenue$1.58B$1.45B$1.62B$1.57B$1.50B$1.54B$1.58B$1.57B$1.54B$1.55B$2.09B$1.56B
    Gross Profit$6.22B$5.51B$6.30B$6.20B$5.58B$5.13B$5.99B$5.97B$5.41B$5.13B$5.02B$5.49B
    Operating Expenses$16.62B$2.93B$4.32B$2.87B$3.11B$2.89B$3.54B$5.08B$2.77B$9.46B$3.41B$2.86B
    R&D$12.95B$1.48B$2.12B$1.52B$1.55B$1.63B$1.63B$1.90B$1.39B$5.65B$1.75B$1.55B
    SG&A$1.92B$1.45B$1.79B$1.36B$1.36B$1.26B$1.91B$1.43B$1.38B$1.38B$1.61B$1.31B
    Operating Income$-10,394,000,000$2.59B$1.98B$3.33B$2.47B$2.24B$2.45B$888.00M$2.64B$-4,322,000,000$1.61B$2.62B
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$247.00M$240.00M$254.00M$256.00M$254.00M$260.00M$248.00M$238.00M$237.00M$254.00M$252.00M$232.00M
    Income Before Tax$-10,254,000,000$2.58B$2.08B$3.64B$2.43B$1.65B$2.17B$956.00M$2.05B$-4,486,000,000$1.65B$2.32B
    Income Tax Expense$242.00M$559.00M$-105,000,000$589.00M$468.00M$334.00M$385.00M$-297,000,000$438.00M$-315,000,000$236.00M$146.00M
    Net Income$-10,496,000,000$2.02B$2.18B$3.05B$1.96B$1.31B$1.78B$1.25B$1.61B$-4,170,000,000$1.42B$2.17B
    EBITDA$-9,309,000,000$3.51B$3.02B$4.58B$3.37B$2.60B$3.11B$1.88B$2.98B$-3,541,000,000$2.59B$3.23B
    EBIT$-10,007,000,000$2.82B$2.33B$3.90B$2.68B$1.91B$2.42B$1.19B$2.29B$-4,231,000,000$1.90B$2.55B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

    Quality meets catalyst: Two regulatory wins in 5 days. Dupixent's AFRS approval + garetosmab Priority Review. Quality Score 98/100. The business is strengthening while the stock trades near fair value. The honest valuation: At $789...

    Glenn Ford
    •
    2/27/26
    •
    177
    Biotech, BioPharma
    Also mentions:
    SNYAMGNTMDXGILD

    Part 2 of 3: The Night the Organ Monopoly Proved It Was Real

    Tonight's earnings confirmed the thesis: Q4 revenue $160.8M (+32%), FY $605.5M (+37%), 5,139 OCS cases (+38%), 2026 guidance $727M–$757M. TMDX has graduated from speculative disruptor to verified logistics monopoly. The 22-aircraft fleet is the moat...

    Glenn Ford
    •
    2/25/26
    •
    147
    healthcare-innovation, Healthcare Stocks
    Also mentions:
    GILDREGN

    Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To

    Gilead's $14.3B Biktarvy franchise grew 7% YoY in 2025, proving HIV isn't ex-growth. Total revenues hit $29.4B. The base business alone justifies ~$150 fair value. Yeztugo (twice-yearly HIV prevention) expands TAM from diagnosed patients to at-risk populations. FDA approved June 2025. $800M combined...

    Glenn Ford
    •
    2/24/26
    •
    139
    Healthcare Stocks, healthcare-innovation
    Also mentions:
    TMDXREGNJNJ

    Eight Weeks in the Dark: What GNG Quant's Live Forward-Alpha Test Actually Revealed

    8 of 9 weekly 5-day windows beat the S&P 500 (89% hit rate), averaging +1.34% alpha per 5-day period. The one clear miss was 2026-01-23 (both surfaces negative), but subsequent runs snapped back positive. 21-day results are the standout: 5 of 5 windows positive...

    Glenn Ford
    •
    2/24/26
    •
    225
    Quant
    Also mentions:
    GILDNVDA

    Pfizer: The 6% Yield Hiding Behind a Post-Pandemic Hangover

    Pfizer trades at 9.6x forward earnings with 6.3% yield; non-COVID portfolio grew 6% operationally in 2025, but market still prices post-pandemic discount GAAP payout ratio of 98.8% is misleading; on adjusted EPS of $3.22...

    Glenn Ford
    •
    2/12/26
    •
    171
    Income Investing, value investing
    Also mentions:
    MRKBMYGILDABBV

    Government Contracts

    Gov Obligations (TTM)
    -$9.51M
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    3
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    GILD Valuation and Fair Value

    P/E
    -403.5x
    Forward P/E
    15.6x
    EV/EBITDA
    121.3x
    P/FCF
    15.1x
    PEG
    2.3x
    P/B
    16.5x
    See GNG's fair value

    GILD Profitability: Margins, ROIC and FCF

    Gross margin
    79.6%
    Operating margin
    33.7%
    Net margin
    -10.6%
    ROIC
    -2.5%
    ROE
    -20.7%
    FCF margin
    42.5%
    FCF yield
    6.6%

    GILD Competitors

    CompanyTicker
    Amgen IncAMGN
    Abbott LaboratoriesABT
    Thermo Fisher Scientific IncTMO
    Novo Nordisk A/SNVO
    AstraZeneca PLCAZN
    Pfizer IncPFE
    Novartis AG ADRNVS
    Danaher CorporationDHR

    Sector: Healthcare

    GILD Analyst Ratings

    Consensus
    Buy
    Analysts
    28
    Strong Buy
    6
    Buy
    16
    Hold
    5
    Sell
    0
    Strong Sell
    1

    GILD Bull Case vs Bear Case

    Bull case

    • GILD converts 42.5% of revenue into free cash flow.
    • GILD beat EPS estimates in 100.0% of its last 8 reported quarters.
    • GILD grew quarterly revenue 10.2% year over year.

    Bear case

    • GILD has a -10.6% net profit margin.
    • GILD has a debt-to-equity ratio of 2.2x.

    GILD Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    9.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $2.16
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    6 up, 14 down

    GILD Dividend

    Forward yield
    2.1%
    Payout ratio
    29.8%
    3Y DPS growth
    2.7%
    5Y DPS growth
    3.0%
    Pay months
    Mar, Jun, Sep, Dec
    GILD dividend history

    Frequently Asked Questions About GILD

    What is GILD's current dividend yield?

    Gilead Sciences Inc (GILD) has a forward dividend yield of 2.08%.

    Does GILD pay dividends?

    Yes, Gilead Sciences Inc pays dividends with a forward dividend yield of 2.08%.

    What is GILD's market cap?

    Gilead Sciences Inc (GILD) has a market capitalization of $190.38B with a current stock price of $157.37.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In